The CEBPA (CCAAT/enhancer binding protein alpha) gene encodes a transcription factor important for granulocyte differentiation. CEBPA mutations are found in 6-15% of de novo acute myeloid leukemia (AML) and in 15-18% of AML with normal karyotypes. CEBPA mutations are associated with favorable prognosis in absence of associated cytogenetic abnormalities and FLT3 internal duplication (FLT3-ITD). Germline CEBPA mutations are a cause of nonsyndromic, familial AML.

Lavender (EDTA), 4mL

Immediately following collection, mix sample thoroughly by gently inverting 8 - 10, times to prevent clotting

Lavender (EDTA), 4 mL

Dk green Sodium heparin (Na hep), no gel

Immediately following collection, mix sample thoroughly by gently inverting 8 - 10, times to prevent clotting

Whole blood

Dk green Sodium heparin (Na hep), no gel

Bone marrow

Lavender (EDTA), 4mL

Dk green Sodium heparin (Na hep), no gel

Molecular Medicare billing request

Hospital clients submitting a request for this assay on an outpatient with Medicare should complete and submit a Molecular Medicare billing request form to notify us of the need for Allina Health Laboratory to bill insurance.

Ambient (preferred)

Specimen does not meet all of the above criteria for sample type, container, minimum volume, collection and storage.

Unsuitable specimens include but are not limited to:

• frozen whole blood or marrow
• a leaking tube
• clotted blood or marrow
• a grossly hemolyzed specimen or otherwise visibly degraded
• specimen suspected of being contaminated by another specimen
• specimen contains specific foreign material

Polymerase chain reaction (PCR), direct sequencing and capillary electrophoresis

An interpretive report will be included

Medical necessity

Hospital clients submitting a request for this assay on an outpatient with Medicare should complete and submit a Molecular Medicare billing request form to notify us of the need for Allina Health Laboratory to bill insurance.

Molecular Medicare billing request